BICO has today been awarded the Swedish Government’s Award, Exporter of the Year 2021. The Award was presented by the Minister for Foreign Trade Anna Hallberg at a ceremony at the Ministry for Foreign Affairs in Stockholm with the attendance of HRH Prince Daniel. The novel Award is initiated by the Swedish government in effort to promote Swedish exports, by honoring companies that have made particularly meritorious efforts in inspiration and development.
The motivation from the Government reads as follows:
"BICO Group is a Swedish success story whose products are designed for the future. By managing to take 3D printing of tissues and organs from the drawing board into reality in more than 65 countries, the Gothenburg company has made it onto the international scene in the field of applications in biotechnology. Together with the development of more than 50 in-house developed bio-inks, BICO Group has also revolutionized research by replacing the use of animal testing with printed human cell tissues. With its very high level of innovation and decisive determination to grow globally, the company is a true role model for the country's future exporting companies.” *
“We are extremely honored and glad to receive this award. At the same time as it a proof of our team’s hard work it also highlights the importance and potential within life science. I am looking forward to continuing to work together with the team towards our mission of solving the health challenges by combining biology, engineering, robotics and technology and spreading our vision of bio convergence and how it can be used to improve global health challenges. I am convinced that we have only yet seen the beginning,” commented Erik Gatenholm, CEO and co-founder, BICO.
To read more about the Government’s Export Awards and the motivation, please visit, www.regeringen.se
*The text is a translation by BICO of the original version in Swedish.
For further information, please contact:
Isabelle Ljunggren, Head of Communications
Phone (Sweden): +46 70 830 0890
This information was submitted for publication, through the agency of the contact persons set out above, on October 22, at 2.30 pm (CEST).
Founded in 2016, BICO (formerly CELLINK) is the leading bio convergence company in the world. By combining different technologies, such as robotics, artificial intelligence, computer science, and 3D bioprinting with biology, we enable our customers to improve people's health and lives for the better.
With a focus on the application areas of bioprinting, multiomics, cell line development, and diagnostics, the company develops and markets innovative technologies that enable researchers in the life sciences to culture cells in 3D, perform high-throughput drug screening and print human tissues and organs for the medical, pharmaceutical, and cosmetic industries. We create the future of health.
The Group’s instruments in the field amounts to 25,000, including all the top 20 pharmaceutical companies, are being used in more than 65 countries, and have been cited in more than 9,500 publications. BICO is listed on Nasdaq Stockholm under BICO. www.bico.com